|
| Study | Population (n) | Study type (data source) | Cardiac disease | CKD | Cardiac-specific outcomes | Outcomes (%) |
|
| Heywood et al., 2007 [39] | N = 118,465
Mean Age 61.7–76.3 yrs
Male 42%–57% | ADHERE registry | ADHF | eGFR 60–89: 27.4%; eGFR 30–59: 43.5%; eGFR 15–29: 13.1%; eGFR < 15: 7% | Use of cardioprotective meds (ACE-I and ARB) decreased with increasing degree of CKD | OR for in-hospital mortality: eGFR ≥ 90: 1.0; eGFR 60–89: 2.3; eGFR 30–59: 3.9; eGFR 15–29: 7.6; eGFR < 15: 6.5 |
| Elsayed et al., 2007 [40] | N = 13826
Mean Age 58 yrs
Male 56% | Prospective (ARIC and CHS) | Baseline CVD in 12.9% | eGFR decrease of at least 15 ml/min/1.73 m2 to a final level < 60 ml/min/1.73 m2 was seen in 34% of patients with baseline CVD | NA | OR for development of kidney disease 1.54 (CVD versus non-CVD) |
| Ahmed et al., 2007 [41] | N total = 7788
Mean Age 59.9–65.4 yrs
Male 76%–81% | Retrospective (DIG trial); Propensity-matched study | Ambulatory patients with CHF | eGFR < 60 in 45% | A graded association was found between CKD-related deaths and LVEF | Matched HR: (CKD versus non-CKD) All-cause death 1.71 |
| Campbell et al., 2009 [42] | N total = 7788
Mean Age 59.9–65.4 yrs
Male 76%–81% | Retrospective (DIG trial); Propensity-matched study | Ambulatory patients with CHF | eGFR < 60 in 45% | Matched HR: (CKD versus non-CKD) CV hospitalization 1.17 HF hospitalization 1.08 CV death 1.24 HF death 1.42 | Matched HR: (CKD versus non-CKD) All-cause hospitalization 1.18 |
| Dimopoulos et al., 2008 [43] | N = 1102
Mean Age 36 yrs
Male 48.5% | Retrospective (single center) | Adult congenital heart disease | eGFR 60%–89 41% eGFR < 60 9% | NA | All-cause death (HR) eGFR ≥ 90 1.0; eGFR < 60 3.25 |
| Hillege et al., 2003 [44] | N = 298
Mean Age 51–67 yrs
Male 70%
DM 16%–27%
HTN 6%–14% | Retrospective (CATS trial) | 1st anterior wall MI | Change in GFRc Placebo: −5.5 ml/min/yr Captopril: −0.5 ml/min/yr | New CHF (RR) GFRc > 103: 1.0 GFRc 81–103: 1.23 GFRc < 81: 1.55 | All-Cause death: 1-yr 8% |
|
